Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18526377 | 1.00 | KCNH2 (0.34) | KCNH2NT5EOPRM1PDE4BKLKB1 | |
| SCHEMBL18526372 | 0.92 | OPRM1 (0.37) | KCNH2NT5EOPRM1HDAC6HPGD | |
| SCHEMBL18526325 | 0.91 | NT5E (0.40) | KCNH2NT5EOPRM1PDE4BKLKB1 | |
| SCHEMBL22416866 | 0.85 | TLR2 (0.41) | NT5EOPRM1HPGDTLR2TP53 | |
| SCHEMBL18526322 | 0.82 | NT5E (0.41) | KCNH2NT5EOPRM1HDAC6RORC | |
| SCHEMBL31696933 | 0.82 | NT5E (0.37) | KCNH2NT5EOPRM1PDE4BHDAC6 | |
| SCHEMBL18526374 | 0.82 | OPRM1 (0.36) | KCNH2NT5EOPRM1HDAC6HPGD | |
| SCHEMBL29406990 | 0.82 | OPRM1 (0.36) | KCNH2NT5EOPRM1HDAC6HPGD | |
| SCHEMBL31476377 | 0.81 | KCNH2 (0.36) | KCNH2NT5EOPRM1HDAC6RORC | |
| SCHEMBL29720293 | 0.81 | NT5E (0.35) | KCNH2NT5EOPRM1PDE4BHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12474345-B2 | Chemigenetic voltage indicators | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-11-18 | — | — | US | disclosed |
| US-12440581-B2 | Fluorophores for super-resolution imaging | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-10-14 | — | — | US | disclosed |
| US-12275767-B2 | Chemigenetic calcium indicators | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4519426-A2 | SPLIT MODIFIED DEHALOGENASE VARIANTS | PROMEGA CORPORATION (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12105122-B2 | Voltage indicators | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240174992-A1 | SPLIT MODIFIED DEHALOGENASE VARIANTS | PROMEGA CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-20230416320-A1 | CHEMIGENETIC CALCIUM INDICATORS | HOWARD HUGHES MEDICAL INSTITUTE | 2023-12-28 | — | — | US | disclosed |
| WO-2023215452-A2 | SPLIT MODIFIED DEHALOGENASE VARIANTS | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230296649-A1 | VOLTAGE INDICATORS | HOWARD HUGHES MEDICAL INSTITUTE | 2023-09-21 | — | — | US | disclosed |
| US-11708397-B2 | Chemigenetic calcium indicators | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11598792-B2 | Voltage indicators | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220299518-A1 | CHEMIGENETIC VOLTAGE INDICATORS | HOWARD HUGHES MEDICAL INSTITUTE | 2022-09-22 | — | — | US | disclosed |
| US-11385236-B2 | Chemigenetic voltage indicators | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12474345-B2 | Chemigenetic voltage indicators | CACNB2, CACNB3, CACNB1 | KCNH2 151/4885NT5E 2048/4885OPRM1 2872/4885 |
| US-11385236-B2 | Chemigenetic voltage indicators | CACNB2, CACNB3, CACNB1 | KCNH2 151/4885NT5E 2048/4885OPRM1 2872/4885 |
| US-20220299518-A1 | CHEMIGENETIC VOLTAGE INDICATORS | CACNB2, CACNB3, CACNB1 | KCNH2 151/4885NT5E 2048/4885OPRM1 2872/4885 |
| US-12440581-B2 | Fluorophores for super-resolution imaging | CHAT, FABP7, CD68 | KCNH2 3377/4885NT5E 1555/4885OPRM1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.